Devyser published recent publications on HLA loss and immune escape after HSCT, and the company is hosting an upcoming webinar on HLA loss mediated immune escape after HSCT.
Public source
Publisher name
Public post
Enjoyed reading our recent publications on HLA loss and immune escape after HSCT? Join our upcoming webinar to explore the science in greater depth. In the webinar: HLA…
Company
Devyser
A new level of certainty
- Industry
- Biotechnology
- Location
- Stockholm, SE
- Company size
- 51–200 employees
About Devyser
Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.
See moreLatest activity
Latest activity from Devyser
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Altum Sequencing
Altum Sequencing published a new white paper exploring ctDNA-based MRD monitoring and cellular therapy kinetics for post-CAR-T therapy in follicular lymphoma.
Research & Knowledge
Natera
Natera published a new public publication in Blood Neoplasia representing an important advancement in lymphoma ctDNA-MRD testing.
Research & Knowledge
SOPHiA GENETICS
SOPHiA GENETICS published exploratory research in Clinical Cancer Research examining how integrated analysis of clinical, genomic, and biomarker data supports understanding of patient heterogeneity in advanced solid tumors treated with combination immunotherapy.
Research & Knowledge
Eclipsebio
Eclipsebio published a review by Ojalvo et al. describing the process of individualized neoantigen therapy across three phases involving formalin-fixed paraffin-embedded tumor blocks, whole blood for germline control and HLA typing, and a CAP/CLIA- and ISO13485-certified lab for histopathology, nucleic acid extraction, and next-generation sequencing.
Research & Knowledge
Algorithmic Biologics